COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR TREATMENT OF CANCER Russian patent published in 2023 - IPC A61K31/165 A61K39/395 A61P35/00 

FIELD: medicine; oncology.

SUBSTANCE: patient with melanoma or non-small cell lung cancer is administered with a combination of therapeutic agents: entinostat and pembrolizumab. In this case, the patient has previously received a PD-1-blocking antibody or a PD-L1-blocking antibody and has progression in previous therapy with the PD-1-blocking antibody or the PD-L1-blocking antibody. Entinostat is administered orally at a dose of 3 mg or 5 mg once a week. Pembrolizumab is administered intravenously at a dose of 200 mg every three weeks, while the duration of a treatment cycle is 21 days.

EFFECT: method allows for an increase in the efficiency of treatment of oncological diseases due to combination and dosage regimen of drugs.

8 cl, 2 ex